Disease associations of mannose-binding lectin and potential of replacement therapy

Indian Journal of Medical Research

Volumn 127, Issue 5, 2008, Pages 431-440

  Gupta, Kshitij ^a   Gupta, R K ^a   Hajela, Krishnan ^a  

^a DEVI AHILYA UNIVERSITY   (India)

Author keywords

Innate immunity; Mannose binding lectin; Recombinant MBL; Recombinant therapy

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; INTERLEUKIN 6; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN 2; RECOMBINANT PROTEIN;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; CANDIDIASIS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; HEPATITIS B; HEPATITIS C; HOST PARASITE INTERACTION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MYCOSIS; OPSONIZATION; PHAGOCYTOSIS; PROTEIN DEFICIENCY; PROTOZOAL INFECTION; RECURRENT INFECTION; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANIMALS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, NATURAL; MANNOSE-BINDING LECTIN; MYCOSES; RECOMBINANT PROTEINS; VIRUS DISEASES;

EID: 51349164411     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol 2006; 67: 247-56.
2. Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: biology and clinical implications. Intern Med J 2005; 35: 548-55.
3. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006; 68: 193-209.
4. Garred P, Larsen F, Seyfarth J, Fujita R. Madsen HO. Mannose-binding lectin and its genetic variants.Genes Immun 2006; 7: 85-94.
5. Thiel S, Frederiksen PD, Jensenius JC.Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol 2006; 43: 86-96.
6. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003; 40: 423-9.
7. Turner MW, Hamvas RM. Mannose-binding lectin: structure, function, genetics and disease associations. Immunogenetics 2000; 2: 305-22.
8. Holmskov U, Malhotra R, Sim RB, Jensenius JC. C ollectins: Collagenous C-type lectins of the innate immune defense system. Immunol Today 1994; 15: 67-74.
9. Kilpatrick DC.Mannan-binding lectin and its role in innate immunity. Transfus Med 2002; 12: 335-52.
10. Neth O, Jack DL, Johnson M, Klein Nj, Turner MW. Enhancement of complement activation and opsonophagocytosis by complexes of mannose-binding lectin with mannose-binding lectin-associated serine protease after binding to Staphylococcus aureus. J Immunol 2002; 169: 4430-6.
11. Neth O, Jack DL, Dodds AW, Holzel H, Klein W, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68: 688-93.
12. Sim RB, Clark H, Hajela K, Mayilyan KR.Collectins and host defence. Novartis Found Symp 2006; 279: 170-81.
13. Mayilyan KR, Presanis JS, Arnold JN, Hajela K, Sim RB.Heterogeneity of MBL-MASP complexes. Mol Immunol 2006; 43: 1286-92.
14. Presanis JS, Hajela K, Ambrus G, Gal P, Sim RB.Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004; 40: 921-9.
15. Hajela K, Kojima M, Ambrus G, Wong KH, Moffatt BE, Ferluga J, et al.The biological functions of MBL-associated serine proteases (MASPs). Immunobiology 2002; 205: 467-75.
16. Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin-a soluble pattern recognition molecule. Mol Immunol 2004; 41: 113-21.
17. Kilpatrick DC.Introduction to mannan-binding lectin. Biochem Soc Trans 2003; 31(Pt 4): 745-7.
18. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180: 86-99.
19. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-20.
20. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein level of mannan-binding lectin in population from southeast Africa and South America. J Immunol 1998; 161: 3169-75.
21. Ezekowitz RA, Day LE, Herman GA. A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med 1988; 167: 1034-46.
22. Dean MM, Minchinton RM, Heatley S, Eisen DP.Mannose binding lectin acute phase activity in patients with severe infection. J Clin Immunol 2005; 25: 346-52.
23. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 1992; 90: 31-5.
24. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314: 1229-32.
25. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, et al. Mannose binding protein gene mutation associated with unusual and severe infection in adults. Lancet 1995; 345: 886-9.
26. Jack DL, Jarvis GA, Booth CL, Turner MW, Klein NJ. Mannose-binding lectin accelerates complement activation and increases serum killing of Neisseria meningitidis serogroup C. J Infect Dis 2001; 184: 836-45.
27. Miller ME, Seals J, Kaye R, Levitsky LC. A familial, plasma associated defect of phagocytosis: a new cause of recurrent bacterial infection. Lancet 1968; ii: 60-3.
28. Candy DC, Larcher VF, Tripp JH, Harries IT, Harvey BA, Soothill JF. Yeast opsonization in children with chronic diarrhoeal states. Arch Dis Child 1980; 55: 189-93.
29. Richardson VF, Larcher VF, Price JF. A common congenital immunodeficiency predisposing to infection and atopy in infancy. Arch Dis Child 1984; 58: 799-802.
30. Soothill JF, Harvey BA. Defective opsonization. A common immune deficiency. Arch Dis Child 1976; 51: 91-9.
31. Turner MW, Mowbray JF, Harvey BA, Brostoff J, Wells RS, Soothill JF. Defective yeast opsonization and C2 deficiency in atopic patients. Clin Exp Immunol 1978; 34: 253-9.
32. Turner MW, Mowbray JF, Roberton DR. A study of C3b deposition on yeast surfaces by sera of known opsonic potential. Clin Exp Immunol 1981; 46: 412-9.
33. Turner MW, Seymour ND, Kazatchkine MD, Mowbray JF. Suboptimal C3b/C3bi deposition and defective yeast opsonization. I Evidence for the absence of essential co-factor activity. Clin Exp Immunol 1985; 62: 427-34.
34. Ikeda K, Sannoh T, Kawasaki N, Kawasaki T, Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem 1987; 262: 7451-4.
35. Super M, Thiel S, Lu J, Levinsky RJ, Turner MW. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989; 2: 1236-9.
36. Babula O, Lazdane G, Kroica J, Linhares IM, Ledger WJ, Witkin SS. Frequency of interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 2005; 40: 1258-62.
37. Devyatyarova-Johnson M, Rees IH, Robertson BD, Turner MW, Klein NJ, Jack DL. The lipopolysaccharide structures of Salmonella enterica serovar Typhimurium and Neisseria gonorrhoeae determine the attachment of human mannose-binding lectin to intact organisms. Infect Immun 2000; 68: 3894-9.
38. Ambrosio AR, De Messias-Reason IJ. Leishmania (Viannia) braziliensis: interaction of mannose-binding lectin with surface glycoconjugates and complement activation. An antibody-independent defence mechanism. Parasite Immunol 2005; 27: 333-40.
39. Hoal-Van Helden EG, Epstein J. Victor TC, Hon D, Lewis LA, Beyers N et al. Mannose binding protein B allele confers protection against tuberculous meningitis. Pediatr Res 1999; 45: 459-64.
40. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A. Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet 1994; 21: 125-31.
41. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349: 236-40.
42. Sasaki K, Tsutsumi A, Wakamiya N, Ohtani K, Suzuki Y, Watanabe Y, et al. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterol 2000; 35: 960-5.
43. Matsushita M, Hijikata M, Matsushita M, Ohta Y, Mishiro S. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 1998; 29: 695-700.
44. Matsushita M, Hijikata M, Ohta Y, Iwata K, Matsumoto M, Nakao K, et al. Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL. Arch Virol 1998; 143: 645-51.
45. Hohler T, Wunschel M, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. Exp Clin Immunogenet 1998; 15: 130-3.
46. Thio CL, Mosbruger T, Astemborski J, Greer S, Kirk GD, O'Brien SJ, et al. Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol 2005; 79: 9192-6.
47. Santos IK, Costa CH, Krieger H, Feitosa MF, Zurakowski D, Fardin B, et al. Mannan-binding lectin enhances susceptibility to visceral leishmaniasis. Infect Immun 2001; 69: 5212-5215.
48. Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68: 688-93.
49. Jack DL, Lee ME, Turner MW, Klein NJ, Read RC. Mannose-binding lectin enhances phagocytosis and killing of Neisseria meningitidis by human macrophages. J Leukoc Biol 2005; 77: 328-36.
50. Bathum L, Hansen H, Teisner B, Koch C, Garred P, Rasmussen K, et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol 2006; 43: 473-9.
51. Geiger AM, Foxman B, Gillespie BW. The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 1995; 85: 1146-8.
52. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993; 36: 153-65.
53. Witkin, Steven S. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same. United State patent US; 20050191667. 2005.
54. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 2003; 37: 733-7.
55. Choi EH, Taylor JG, Foster CB, Walsh TJ, Anttila VJ, Ruutu T, et al. Common polymorphisms in critical genes of innate immunity do not contribute to the risk for chronic disseminated candidiasis in adult leukemia patients. Med Mycol 2005; 43: 349-53.
56. Liu F, Liao Q, Liu Z. Mannose-binding lectin and Vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92: 43-7.
57. Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004; 190: 632-40.
58. Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006; 193: 1589-97.
59. Pellis V, De Seta F, Crovella S, Bossi F, Bulla R, Guaschino S, et al. Mannose binding lectin and C3 act as recognition molecules for infectious agents in the vagina. Clin Exp Immunol 2005; 139: 120-6.
60. Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT. Interaction of marmose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 2000; 81: 949-55.
61. Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med 1989; 169: 185-96.
62. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, et al. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 2004; 20: 327-35.
63. Boniotto M, Crovella S, Pirulli D, Scarlatti G, Spano A, Vatta L, et al. Polymorphisms in the MBL2 promoter correlated with risk of HIV-1 vertical transmission and AIDS progression. Genes Immun 2000; 1: 346-8.
64. Crovella S, Bernardon M, Braida L, Boniotto M, Guaschino S, Ferrazzi E, et al. Italian multicentric pilot study on MBL2 genetic polymorphisms in HIV positive pregnant women and their children. J Matern Fetal Neonatal Med 2005; 17: 253-6.
65. Malik S, Arias M, Di Flumeri C, Garcia LF, Schurr E. Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population, Immunogenetics 2003; 55: 49-52.
66. Senaldi G, Davies ET, Mahalingam M, Lu J, Pozniak A, Peakman M, et al. Circulating levels of mannose binding protein in human immunodeficiency virus infection. J Infect 1995; 31: 145-8.
67. Prohaszka Z, Thiel S, Ujhelyi E, Szlavik J, Banhegyi D, Fust G. Mannan-binding lectin serum concentrations in HIV-infected patients are influenced by the stage of disease. Immunol Lett 1997; 58: 171-5.
68. Arai T, Tabona P, Summerfield JA. Human mannose-binding protein gene is regulated by interleukins, dexamethasone and heat shock. Q J Med 1993; 86: 575-82.
69. Heggelund L, Mollnes TE, Espevik T, Muller F, Kristiansen KI, Aukrust P, et al. Modulatory effect of mannose-binding lectin on cytokine responses: possible roles in HIV infection. Eur J Clin Invest 2005; 35: 765-70.
70. Hundt M, Heiken H, Schmidt RE. Low mannose-binding lectin serum concentrations in HIV long-term nonprogressors?. AIDS Res Hum Retroviruses 2000; 16: 1927.
71. Amoroso A, Berrino M, Boniotto M, Crovella S, Palomba E, Scarlatti G, et al. Polymorphism at codon 54 of mannose-binding protein gene influences AIDS progression but not HIV infection in exposed children. AIDS 1999; 13: 863-4.
72. Vallinoto AC, Menezes-Costa MR, Alves AE, Machado LF, de Azevedo VN, Souza LL, et al. Mannose-binding lectin gene polymorphism and its impact on human immunodeficiency virus 1 infection. Mol Immunol 2006; 43: 1358-62.
73. World Health Organization. Hepatitis B fact sheet number 204. Available at http://www.who.int/mediacentre/factsheets/fs204/en/accessed on 16.12.2005.
74. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
75. Yuen MF, Lau CS, Lau YL, Wong WM, Cheng CC, Lai CL. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999; 29: 1248-51.
76. Chong WP, To YF, Ip WK, Yuen MF, Poon T?, Wong WH, et al. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 2005; 42: 1037-45.
77. Song le H, Binh VQ, Duy DN, Juliger S, Bock TC, Luty AJ, et al. Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat Res 2003; 522: 119-25.
78. Cheong JY, Cho SW, Lim SK, Shin do H, Yoon SK, Lee JE, et al. Lack of association between hepatitis B virus infection and polymorphism of mannose-binding lectin gene in Korean population. J Korean Med Sci 2005; 20: 65-9.
79. Holmskov U, Thiel S, Jensenius JC. Collectins and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21: 547-78.
80. Davies EJ, Snowden N, Hillarby MC, Carthy D, Grennan DM, Thomson W, et al. Mannose binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995; 38: 110-14.
81. Ip WK, Chan SY, Lau CS, Lau YL. Association of systemic lupus erythematosus with promoter polymorphisms of the mannose-binding lectin gene. Arthritis Rheum 1998; 41: 1663-8.
82. Garred P, Madsen HO, Halberg P, Petersen J, Kronborg G, Svejgaard A, et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2145-52.
83. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351: 260-7.
84. Horiuchi T, Tsukamoto H, Morita C, Sawabe T, Harashima S, Nakashima H, et al. Mannose binding lectin (MBL) gene mutation is not a risk factor for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Japanese. Genes Immun 2000; 1: 464-6.
85. Graudal NA, Homann C, Madsen HO, Svejgaard A, Jurik AG, Graudal HK, et al. Mannan binding lectin in rheumatoid arthritis. A longitudinal study. J Rheumatol 1998; 36: 207-9.
86. Graudal NA, Madsen HO, Tarp U, Svejgaard A, Jurik G, Graudal RK, et al. The association of variant mannose-binding lectin genotypes with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2000; 43: 515-21.
87. Kruse C, Rosgaard A, Steffensen R, Varming K, Jensenius JC, Christiansen OB. Low serum level of mannan-binding lectin is a determinant for pregnancy outcome in women with recurrent spontaneous abortion. Am J Obstet Gynecol 2002; 187: 1313-20.
88. Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, Bardy P, et al. Interleukins-1, -4, -6, -10, tumor necrosis factor, transforming growth factor-beta, FAS, and mannose-binding protein C gene polymorphisms in Australian women: Risk of preterm birth. Am J Obstet Gynecol 2004; 191: 2056-67.
89. Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet 1998; 352: 959-60.
90. Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir G, Vikingsdottir T, Gudnason V, et al. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med 2005; 201: 117-25.
91. Ma Y, Uemura K, Oka S, Kozutsumi Y, Kawasaki N, Kawasaki T. Antitumor activity of marman binding protein in vivo as revealed by a virus expression system: mannan- binding protein dependent cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1999; 96: 371-5.
92. Casanova JL, Abel L. Human mannose-binding lectin in immunity: Friend, foe, or both? J Exp Med 2004; 199: 1295-9.
93. Klein NJ. Mannose-binding lectin: do we need it? Mol Immunol 2005; 42: 919-24.
94. Dahl M, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG.A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004; 199: 1391-9.
95. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001; 285: 1316-21.
96. Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summerfield JA, et al. High frequencies in African and non- African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992; 1: 709-15.
97. Seyfarth J,Garred P, Madsen HO. The 'involution' of mannose-binding lectin. Hum Mol Genet 2005; 14: 2859-69.
98. Verdu P, Barreiro LB, Patin E, Gessain A, Cassar O, Kidd JR, et al. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum Mol Genet 2006; 15: 2650-8.
99. Boldt AB, Culpi L, Tsuneto LT, de Souza IR, Kun JE, Petzl-Erler ML. Diversity of the MBL2 gene in various Brazilian populations and the case of selection at the mannose-binding lectin locus. Hum Immunol 2006; 67: 722-34.
100. Valdimarsson H, Stefansson M, Vikingsdottir T, Arason GJ, Koch C, Thiel S, et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL)to MBL-deficient humans. Scand J Immunol 1998; 48: 124-6.
101. Valdimarsson H, Infusion of plasma derived mannan binding lectin (MBL) into MBL deficient humans. Biochem Soc Trans 2003; 31 (Pt 4): 768-9.
102. Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, et al. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease.Pediatr Pulmonol 2002; 33: 201-7.
103. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104: 431-7.
104. Jensenius JC, Jensen PH, McGuire K, Larsen JL, Thiel S. Recombinant mannan-binding lectin (MBL) for therapy. Biochem Soc Trans 2003; 31 (Pt 4): 763-7.
105. Cooperative Research Centre for Vaccine Technology (CRC-VT) established and supported from the Australian Governments Co-operative Research Centre Program: Available at http://www.crc-vt.qimr.edu.au/research/ passiveimmunity/mbl.html
106. Natimmune A/S Biotech Company: Denmark, www.natimmune.com
107. Petersen KA, Matthiesen F, Agger T, Kongerslev L, Thiel S, Cornelissen K, et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol 2006; 26: 465-75.